Greetings!
Over and over again this year, I've been moved by your incredible acts of kindness and generosity. In 2022, our community of supporters, sponsors, donors, partners, staff, and board gave their time, talents, and treasures to live out our shared purpose and fund advanced, innovative research that treats the cancer and spares the patient. Together, we continue on the path forward to improve the lives of cancer patients, better our communities, and celebrate survivorship.
I am proud to share some breathtaking progress your generosity made possible in 2022:
- Supported treatment that reduced and depleted lung cancer cells using T-cells
- Continued advancing research in immunotherapy treatments for epithelial ovarian cancer
- Funded an FDA-approved CAR-T cell treatment for pediatric acute lymphoblastic leukemia
- Funded a colorectal clinical trial in honor of famed Peanuts Cartoonist Charles Schulz's 100th birthday
- Continued funding breakthrough immunotherapy research for glioblastoma multiforme, the most aggressive form of brain cancer
- Funded a clinical trial in CAR-T that focuses on treatment at earlier stages of cancer, countering side effects and safely delivering treatments more effectively
- Funded a grant uniting scientists in research aimed at understanding and targeting the genomic complexities of cancer
In collaboration with our board, we worked with 14 corporate partners this year to elevate our shared desire for better outcomes for those diagnosed with cancer. We will continue to grow our impact along with our current and new corporate partners through the power of corporate responsibility.
While 2022 is coming to a close, there is still time to contribute and safeguard our advances from 2022 into 2023 and beyond. Thank you for your ongoing support of CARES and for powering transformative cancer research with us. It is a testament to our combined efforts as one team that the unwavering dedication and spirit of CARES thrives.
My best wishes to you and yours for a blessed New Year.
With gratitude,
‌
‌
‌
‌